Allakos Inc. Stock price

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
1.36 USD +1.49% Intraday chart for Allakos Inc. +8.80% -50.18%
Sales 2023 * - Sales 2024 * - Capitalization 117M
Net income 2023 * -167M Net income 2024 * -127M EV / Sales 2023 * -
Net cash position 2023 * 109M Net cash position 2024 * 76.61M EV / Sales 2024 * -
P/E ratio 2023 *
-0.69 x
P/E ratio 2024 *
-0.92 x
Employees 123
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.24%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Allakos Inc.

1 day+1.49%
1 week+8.80%
Current month+7.09%
1 month+15.25%
3 months-20.93%
6 months-54.21%
Current year-50.18%
More quotes
1 week
1.22
Extreme 1.22
1.39
1 month
1.15
Extreme 1.15
1.50
Current year
1.00
Extreme 1
3.36
1 year
1.00
Extreme 1
6.74
3 years
1.00
Extreme 1
127.05
5 years
1.00
Extreme 1
157.98
10 years
1.00
Extreme 1
157.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 17-03-31
President 54 17-03-31
Director of Finance/CFO 54 21-04-18
Members of the board TitleAgeSince
Director/Board Member 66 16-03-31
Chairman 58 17-02-28
Chief Executive Officer 54 17-03-31
More insiders
Date Price Change Volume
24-02-23 1.36 +1.49% 417,006
24-02-22 1.34 +3.88% 656,823
24-02-21 1.29 +5.74% 566,314
24-02-20 1.22 -2.40% 1,095,337
24-02-16 1.25 -1.57% 1,774,796

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. It is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.36 USD
Average target price
2.9 USD
Spread / Average Target
+113.24%
Consensus
1st Jan change Capi.
-50.18% 117 M $
+5.71% 110 B $
+11.72% 104 B $
+9.93% 23 902 M $
-10.96% 22 243 M $
-26.36% 21 573 M $
-6.59% 18 925 M $
-14.01% 16 036 M $
+1.84% 13 271 M $
+41.59% 12 608 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Allakos Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer